SCHEMBL7303141

SCHEMBL7303141

CCC=C(C)C(=O)OC(C)(C)C

nearest known ligand 0.31

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.31
GAA P10253 1/20 0.31
CA12 O43570 1/20 0.30
CA1 P00915 1/20 0.30
CA7 P43166 1/20 0.30
CA14 Q9ULX7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7303138 1.00 DGAT1 (0.31) DGAT1GAACA12CA1CA7
SCHEMBL28558830 0.83 ALDH1A1 (0.31)
SCHEMBL27458532 0.81
SCHEMBL11231291 0.81 MTNR1A (0.30) DGAT1GAA
SCHEMBL9799762 0.80 EP300 (0.36)
SCHEMBL9799758 0.80 EP300 (0.36)
SCHEMBL27085742 0.79 ALDH1A1 (0.32)
Hydrochloric Acid SCHEMBL11324560 0.79 GABRR1 (0.30)
SCHEMBL7429337 0.79 EP300 (0.43)
SCHEMBL7429328 0.79 EP300 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170340547-A1 AGENTS AND METHODS FOR THE TEMPORARY SHAPING OF KERATIN-CONTAINING FIBERS HENKEL AG & CO. KGAA (DE) 2017-11-30 US claimed
CN-112661738-B Flavanone compound and preparation method and application thereof 南方医科大学 2023-01-10 CN disclosed
CN-108640168-B Drainage mechanism suitable for sewage treatment 浙江财经大学 2021-07-23 CN disclosed
CN-107434866-B Water-based blend compositions and methods of making the same 陶氏环球技术有限责任公司 2021-05-28 CN disclosed
US-20170340547-A1 AGENTS AND METHODS FOR THE TEMPORARY SHAPING OF KERATIN-CONTAINING FIBERS HENKEL AG & CO. KGAA (DE) 2017-11-30 US disclosed
CN-102753476-B Carbon nanotube sheet material and manufacture method thereof NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2015-08-26 CN disclosed
EP-0780386-B1 Matrix metalloprotease inhibitors HOFFMANN LA ROCHE (CH) 2002-10-02 EP disclosed
US-5932595-A ANTIARTHRITIC AGENT; MULTIPLE SCLEROSIS; OSTEOPOROSIS; RESPIRATORY SYSTEM DISORDERS; SKIN DISORDERS; ANTIULCER AGENT SYNTEX (U.S.A.) INC. (US) 1999-08-03 US disclosed
EP-0780386-A1 Matrix metalloprotease inhibitors F. HOFFMANN-LA ROCHE AG (CH) 1997-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170340547-A1 AGENTS AND METHODS FOR THE TEMPORARY SHAPING OF KERATIN-CONTAINING FIBERS KRT18, CUTA, TUBA1A DGAT1 3097/4885GAA 3608/4885CA12 2085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.